secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046065
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla reports Q4 net loss $14.9M, cuts workforce 30% to extend runway to 1H 2026 clinical readouts
--------------------------------------------------------------------------------

- Net loss $14.9M in Q4 2024 vs $26.9M Q4 2023; cash $49.0M at year-end vs $111.5M.
- Workforce reduction of over 30%; estimated $0.5-$0.6M in severance costs mostly in Q2 2025.
- BA3182 (CAB-EpCAM x CAB-CD3) Phase 1 dose escalation ongoing; data readout mid-2025; expansion data 1H 2026.
- Mecbotamab vedotin (CAB-AXL-ADC): 66% 1-year OS, 58% 2-year OS in mKRAS NSCLC; median OS not reached.
- Ozuriftamab vedotin (CAB-ROR2-ADC): 45% ORR (confirmed/unconfirmed) in HPV+ SCCHN; partnering discussions Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017025046065/0000950170-25-046065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017025046065/bcab-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer